Acer Therapeutics Inc

Acer Therapeutics — Opexa Therapeutics — Investor Presentation (March 2014)

38 slides from Acer Therapeutics's investor presentation, Mar 24, 2014

  1. Slide 1: Opexa Therapeutics, Precision Immunotherapy

    Opexa Therapeutics, Inc. NASDAQ: OPXA Precision Immunotherapy March 2014 The Woodlands, TX Precision Immunotherapy TM

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements• This investor presentation contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements contained in thi

  3. Slide 3: Introduction to Opexa

    3 Introduction to Opexa • Antigen specific T-cell immunotherapy platform – Potential to address multiple therapeutic areas – Lower capital intensity by leveraging existing GMP manufacturing – Strong Patent Estate: 50 patents issued on T-cell platform (domestic and international) • Lead Program: Tcel

  4. Slide 4: Progress Update

    4 Progress Update • Clinical – As of February 27, 2014, Opexa has randomized over 80% of the expected total number of patients in the Abili-T study in SPMS – Expect completion of enrollment in Q2 2014 – Top line data expected in Mid 2016 • Financial – As of December 31, 2013, Opexa had $23.6 million

  5. Slide 5: Tcelna in Secondary Progressive MS

    5 Tcelna in Secondary Progressive MS SPMS 450,000 Individuals in North America diagnosed with MS; 30-45 % potentially have an SPMS diagnosis Market Size: $7 Billion (est.) RRMS, CIS, PPMS • Potential SPMS market in North America alone could exceed $7 billion • Roughly 150,000 SPMS patients in North

  6. Slide 6: The Root Cause of Multiple Sclerosis: Activated T-cells

    The Root Cause of Multiple Sclerosis: Activated T- cells Degrade Myelin and Damage Myelin Producing Cells In MS patients, the faulty immune system is not able to prevent the attack of a small sub- population of myelin reactive T-cells (MRTC) Myelin Reactive T-cells (MRTC) cross the blood brain barri

  7. Slide 7: Tcelna Consists of Attenuated Antigen Specific T-cell Clones

    7 Tcelna® Consists of Attenuated Antigen Specific T-cell Clones • Therapeutic dose of Tcelna (attenuated T-cell clones) is injected subcutaneously • Immune system recognizes the large volume of cells (30-45 million) under the skin as potential foreign pathogens • We believe Tcelna triggers an immune

  8. Slide 8: Tcelna Could Address the Root Cause of Multiple Sclerosis

    8 Tcelna Could Address the Root Cause of Multiple Sclerosis by Preventing Demyelination and Enabling Remyelination Adapted by permission from Macmillan Publishers Ltd: NATURE REVIEWS IMMUNOLOGY 3, 483-492 (June 2003), copyright (2003) Opexa’s Strategy Tcelna programs the immune system to specificall

  9. Slide 9: Mechanism of Action: Reduction in Myelin Reactive T-Cells

    9 Mechanism of Action Reduction in Myelin Reactive T-Cells -100% -90% -80% -70% -60% -50% -40% -30% -20% -10% 0% Week 0 Week 5 Week 13 Week 21 Week 28 Week 52 Results from Tcelna dose ranging studies: Published in Clinical Immunology (2009) 131, 202-215 Reduction in MRTC Dose 2 Dose 3 Dose 4 Each do

  10. Slide 10: Single Cycle Manufacturing Process

    10 Single Cycle Manufacturing Process: Annual course of treatment (5 doses) from one blood draw Cryopreservation Formulation/ Irradiation of each dose as required Administration: 5 subcutaneous injections/year Manufacturing and QC Dispensation 35 days Epitope Profiling 1 day 14 days - Red Cross - Bl

  11. Slide 11: Merck Serono Agreement for MS indication

    11 Merck Serono Agreement for MS indication • February 2013 option and license agreement with Merck Serono – Up to $220 million in additional payments • Option exercise $25 million for starting Phase III/ or $15 million if another Phase II • $35 million FDA filing, approval and commercialized in US

  12. Slide 12: Tcelna Development Program

    12 Tcelna Development Program Broad Spectrum of MS patients treated Phase Completion Dates Population Total N Treatment Duration (months) Tcelna Placebo Baylor 1998 RRMS, PPMS, SPMS (26) 114 Up to 24 months 114 Phase I dose escalation 2006 RRMS (5) SPMS (6) 16 12 16 - Phase I/II Open label retreatme

  13. Slide 13: TERMS Study - Prospective Analysis in More Active or Progressive Patients

    13 TERMS Study - Prospective Analysis in More Active or Progressive Patients Sub-population of patients (n=50) with more progressed/active disease profile (baseline ARR >1) 2.4 2.23 2.2 2.39 2.1 2.15 2.2 2.25 2.3 2.35 2.4 2.45 EDSS Score ( Mean) Baseline Week 52 Tcelna Placebo (p=0.045) 0.28 0.63 0

  14. Slide 14: Tcelna Stabilizes Disease in SPMS at 2 Years

    14 Tcelna Stabilizes Disease in SPMS at 2 Years 80% 20% 40% 0% 20% 40% 60% 80% 100% Percent of Patients Showing Disease Stabilization Stabilization vs. Historical Progression Stable Progressed 80% of subjects treated with Tcelna showed no further disease progression by EDSS at 2 years Historical Dis

  15. Slide 15: Abili-T: Landmark trial in SPMS

    15 Abili-T : Landmark trial in SPMS• Abili-T Phase IIb clinical trial in SPMS is ongoing – Double-blind, 1:1 randomized, placebo-controlled– Inclusion criteria: Secondary Progressive MS with EDSS of 3 to 6– Immune Monitoring program conducted on a blinded basis• Fast Track designation granted by FDA

  16. Slide 16: Efficacy Assessments

    16 Efficacy Assessments • Primary Endpoint– Whole-brain atrophy• Secondary Endpoints– Sustained progression measured by EDSS– Time to sustained progression– T2 lesions progressing to hypointense lesions (black holes)– Change in EDSS– Annualized Relapse Rate (ARR)– Change in MSFC Assessment of disabi

  17. Slide 17: Immune Monitoring Program

    17 Immune Monitoring Program Phenotypical Analysis (CD4 and CD8) Pro -inflammatory Anti-inflammatory TH1 Treg TH17 Tr1 TH2 IL-2 IL-4 IL-6 IL-5 IL-12 IL-10 IL-17E, IL-17F IL-23 IL-27 TNFα TGFβ IFNϒ BDNF Plausible indicators of Tcelna efficacy • Reduction in Th1/TH17 • Increase in Treg/Tr1 cells • Red

  18. Slide 18: Financials

    18 Financials Cash and Cash Equivalents (MM) as of December 31, 2013 $23.6 Shares outstanding (MM) as of March 1, 2014 27.7 Warrants (MM) (1) 3.1 Stock Options (MM) (2) 2.2 (1) Weighted average exercise price $4.12 as of December 31, 2013 (2) Weighted average exercise price = $3.06 as of March 1, 20

  19. Slide 19: Experienced Management Team and Board of Directors

    19 Experienced Management Team and Board of Directors Neil Warma, President & CEO, Director 19+ years international healthcare experience with large Pharma and emerging biotechnology companies › Former SeniorManagement, Novartis Pharmaceuticals, Basel, Switzerland Former CEO, Viron Therapeutics, Inc

  20. Slide 20: SPMS Scientific Advisory Board

    20 SPMS Scientific Advisory Board Dawn McGuire, M.D., FAAN (Chair)• Advisory Council of the Gill Heart Institute• Former Vice President of Clinical Research at Elan Pharmaceuticals Hans-Peter Hartung, M.D• Chair of Neurology at Heinrich-Heine University, Düsseldorf• Executive Board member of ECTRIMS

  21. Slide 21: Investment Thesis

    21 Investment Thesis• T-cell platform company with Fast Track designation in SPMS• Strong Intellectual property with 50 issued patents (domestic and international)• Esteemed Scientific Advisory Board• Precision Immunotherapy potentially optimizes benefit-risk profile• Targeting an unmet medical need

  22. Slide 22: Appendix

    ©e OPEXA THERAPEUTICS APPENDIX

  23. Slide 23: Tcelna Highlights

    23 Tcelna® Highlights • Clinical studies conducted in Relapsing Remitting and Secondary Progressive MS • Progress made on manufacturing with focus on commercially viable process─ Over 850 Tcelna preparations have been successfully manufactured, reproducible and consistent • Safety demonstrated and t

  24. Slide 24: Tcelna Manufacturing: Personalization followed by Expansion Step

    24 Tcelna Manufacturing: Personalization followed by Expansion Step The Epitope Profiling Assay (EPA) • Screen peripheral blood for Myelin-Reactive T-cells (MRTCs), and mapping of immunodominant epitopes to MBP, MOG and PLP– 109 overlapping peptides encompassing MBP, MOG and PLP– Interferon gamma re

  25. Slide 25: Tcelna Manufacturing: Precision Medicine

    25 Year 2 Year 3 Tcelna Manufacturing: Precision Medicine Proprietary Assay Enables Annual Personalized Treatments Year 1 Conduct analysis of 109 peptides from all three key myelin proteins (MBP, MOG, PLP) • Re-assess epitope profile annually to identify epitope shift • Develop newly personalized fo

  26. Slide 26: TERMS Study: A Completed Phase IIb Clinical Trial in RRMS

    26 • Completed Phase IIb clinical trial in 150 RRMS patients; 33 sites in U.S. • mITT population (n=142)• 37% reduction in ARR vs. placebo• ARR 0.214 vs. 0.339• Superior safety and promising efficacy trend demonstrated• Two End-of-Phase II meetings with FDA successfully completed 0.214 0.339 0 0.05

  27. Slide 27: Safety Summary

    27 Safety Summary Deaths • No deaths occurred Serious Adverse Events (SAEs) • No treatment-related SAEs Most common adverse events • Mild to moderate injection site reaction TERMS Study: Safety Overview

  28. Slide 28: TERMS Study - Subgroup Analysis in Patients Naïve to DMT

    28 TERMS Study - Subgroup Analysis in Patients Naïve to DMT Annualized relapse rate in DMT naïve populations. ARR in placebo subjects without previous disease modifying treatment (DMT) experience reflects relapse rates commonly seen in other placebo controlled trials in MS. In this subpopulation, tr

  29. Slide 29: Secondary Progressive MS: Overview of Phase I/II Patients

    29• 36 SPMS patients treated in three clinical studies– 35 of these patients were treated with Tcelna for two years– 26 patients treated at Baylor; 10 patients treated by Opexa• Promising efficacy observed– Disease stabilization as measured by EDSS was observed in 80% of patients at two years (compa

  30. Slide 30: Tcelna Reduces Annualized Relapse Rate in SPMS

    30 Tcelna Reduces Annualized Relapse Rate (ARR) in SPMS at 2 years Annualized Relapse Rate ( ARR) 0.00 0.10 0.20 0.30 0.40 0.50 0.60 Baseline 12 Months 24 Months In 21.8 years of cumulative patient follow up, only 1 patient experienced 1 relapse One relapse observed in 21 years of cumulative patient

  31. Slide 31: Tcelna Stabilizes Quality of Life Scores in SPMS

    31 Tcelna Stabilizes Quality of Life Scores in SPMS at 2 years 0.9% 1.2% 2.1% -5.1%-6.0%-4.0%-2.0% 0.0% 2.0% 4.0% Physical Psychological 12 Month 18-24 Month Negative percent change indicates improvement from baseline Following two years of treatment, no worsening of physical condition and improveme

  32. Slide 32: Efficacy Assessments: Abili-T Treatment and Assessment Schedule

    32 Efficacy Assessments EDSS: Expanded Disability Status Scale NEURO: Neurological Examination SDMT: Symbol Digit Modalities Test MSFC: MS Functional Composite MSQLI: MS Quality of Life Indicator MRI: Magnetic Resonance Imaging T 500 mL Procurement Immune Monitoring Tcelna dose Abili-T Annual Treatm

  33. Slide 33: Mechanism of Action

    33 Mechanism of Action• Attenuated, patient-specific (autologous) myelin reactive Tcells (MRTC)– MRTC expanded ex vivo in response to immunodominant peptides of MBP, MOG and PLP • Therapeutic sc dosing (30-45 x 106 cells) stimulates host reactivity to the ‘over-represented’ MRTC inducing a dominant

  34. Slide 34: Mechanism of Action: Tcelna increases Tr1 cells in SPMS Patients

    34 Mechanism of Action Tcelna increases Tr1 cells in SPMS Patients Clinical findings in Tcelna treated patients • All three patients (who had experienced relapse in preceding 12-24 month) remained relapse free during the 52-week assessment• Showed stabilization of disease progression• Showed a 57%-6

  35. Slide 35: Mechanism of Action: The Immunopathology of SPMS

    35 Mechanism of Action The Immunopathology of SPMS• SPMS is associated with compartmentalized CNS inflammatory cells- Microglia activation suggests ongoing chronic innate immune responses• SPMS is associated with inflammatory processes localized within the central nervous system- Mechanisms responsi

  36. Slide 36: Baseline Abili-T patients versus Healthy Individuals

    36 Baseline Abili-T patients versus Healthy Individuals CD4+ TR1: CD4+CD45RA-LAG3+CD49b+ % of CD4+ T cells 0 1 2 3 4 ** ** (p=0.01) Healthy Donors SPMS Patients SPMS subjects have a reduced frequency of IL-10 secreting TR1 cells ACTRIMS 2013 Poster: Profiling of Secondary Progressive MS by Multicolo

  37. Slide 37: SPMS subjects have reduced nTReg cells

    37 SPMS subjects have reduced nTReg cells (another type of CD4 cells) Foxp3+ nTregs: CD4+CD127-CD25bright Foxp3+ % of CD4+ T cells 0.0 0.2 0.4 0.6 0.8 1.0 * * (p=0.06) Healthy Donors SPMS Patients Foxp3+ nTregs: CD4+CD127-CD25bright Foxp3+ MFI 0 5000 10000 15000 20000 25000 (p= 0.56) Healthy Donors

  38. Slide 38: SPMS patients have fewer Anti-inflammatory monocytes

    38 SPMS patients have fewer Anti-inflammatory monocytes (PDL1 and HLA-G) PD-L1+ Monocytes: CD14+CD16-ICOS+PD-L1+ % of Conv Monocytes 0 2 4 6 ** ** (p=0.004) mHealthy Donors SPMS Patients HLA-G+ Monocytes: CD14+CD16-ICOS+HLA-G+ % of Conv Monocytes 0.0 0.5 1.0 1.5 2.0 (p=0.164) Healthy Donors SPMS Pat

Opexa Therapeutics — Investor Presentation (March 2014) on 6ix